Summary/Journal Review: Buprenorphine for Treatment of Neonatal Abstinence Syndrome (NAS) 1
|
|
- Lester Wilcox
- 6 years ago
- Views:
Transcription
1 THE 2017 AUTISM SPECTRUM DISORDER & INTELLECTUAL DEVELOPMENTAL DISORDER: FLORIDA BEST PRACTICE PSYCHOTHERAPEUTIC MEDICATION RECOMMENDATIONS FOR TARGET SYMPTOMS IN CHILDREN AND ADOLESCENTS ARE NOW AVAILABLE! The 2017 Autism Spectrum Disorder and Intellectual Developmental Disorder: Florida Best Practice Psychotherapeutic Medication Recommendations for Target Symptoms in Children and Adolescents were updated to provide broad treatment recommendations for common behavioral symptoms, such as hyperactivity, impulsivity, and inattention, seen in children with Autism Spectrum Disorder and/or Intellectual Disability who may present in the primary care setting. Visit our website medicaidmentalhealth.org to view these guidelines. Please contact Sabrina Singh at if you would like hardcopies of the guidelines. THE PHARMACIST S CORNER The Pharmacist s Corner of our newsletter is devoted to providing prescribers with the most current information on psychotherapeutic drugs and mental health treatment. The Pharmacist s Corner is written by Thea Moore, PharmD, BCPP. Dr. Moore is an Associate Professor in the Department of Pharmacotherapeutics and Clinical Research at the University of South Florida College of Pharmacy. Summary/Journal Review: Buprenorphine for Treatment of Neonatal Abstinence Syndrome (NAS) 1 Thea Moore, PharmD, BCPP Current standard of pharmacological treatment for neonatal abstinence syndrome is an opioid, with morphine being the most commonly used. Yet, there is insufficient data to guide the selection of an opioid. Pregnant women with opioid use disorder are commonly treated with either methadone or buprenorphine. While methadone is the current standard treatment, there is growing clinical evidence for buprenorphine leading to less neonatal abstinence syndrome in infants born to these mothers. 2 There is increasing interest in treating pregnant women with opioid use disorder with buprenorphine, as well as the neonates born to this population of women with buprenorphine to treat symptoms of NAS. (Continued on next page)
2 THE PHARMACIST S CORNER Summary/Journal Review: Buprenorphine for Treatment of Neonatal Abstinence Syndrome (NAS) 1 continued On May 4, 2017 New England Journal of Medicine published a study comparing outcomes for buprenorphine versus morphine treatment in neonates with neonatal abstinence syndrome (NAS). This was a single-site, randomized, double-blind, double-dummy clinical trial. Included in the clinical trial were 63 term infants ( 37 weeks of gestation) who had been exposed to opioids in-utero and who had signs of the neonatal abstinence syndrome. Infants with in utero exposure to benzodiazepines were excluded from the trial. Mothers were predominantly enrolled in an outpatient methadone treatment program. Infants were stratified based on maternal self-declaration of feeding plans based on breast-feeding versus bottle-feeding. Infants were randomly assigned to receive either sublingual buprenorphine or oral morphine. Those infants who were not controlled with the maximum dose of opioid were treated adjunctively with phenobarbital. The primary endpoint of the study was duration of treatment for symptoms of neonatal opioid withdrawal. Secondary clinical endpoints included length of hospital stay, percentage of infants who required adjunctive phenobarbital treatment, and safety. The study found that the median treatment duration was significantly shorter with buprenorphine as compared to morphine (15 days versus 33 days) as well as a shorter median length of hospital stay (21 days versus 33 days) (P<0.001 for both comparisons). Adjunctive phenobarbital was administered to 15% of infants in the buprenorphine group as compared to 23% in the morphine group (P=0.36). The rates of adverse effects were similar in the two groups. Study limitations include a small sample size, most infants having mothers in methadone treatment programs, and exclusion of infants with in-utero exposure to benzodiazepines. It would also be helpful to have comparison to other opioids such as long-acting opiates like methadone. The authors concluded that sublingually administered buprenorphine was significantly more effective than oral morphine in reducing duration of treatment for neonatal abstinence syndrome, which in turn led to a decreased length of stay in the hospital. It was also concluded that the two drugs had similar safety profiles. References: 1. Kraft WK, Adeniyi-Jones SC, Chervoneva I, et al. Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome. The New England journal of medicine. May Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. The New England journal of medicine. Dec ;363(24): page 2
3 THE PHARMACIST S CORNER Substance Use Disorder: The Pharmacist s Perspective Summary Thea Moore, PharmD, BCPP, Vanita Sahasranaman, MD Recent statistics regarding substance use in Florida, and particularly opioid use, has been staggering. Florida was one of the few states that showed a statistically significant increase in the drug overdose death rate from 2014 to 2015 ( Drug Overdose Death Data, CDC, 2016). 1 In 2013, the National Institute on Drug Abuse (NIDA) identified South Florida as the location of a heroin epidemic with a 120% increase in heroin deaths from 2011 to 2012 (NIDA, 2014). 2 There has been some success with measures implemented such as the Prescription Drug Monitoring Program started in 2011, increased naloxone access by allowing pharmacist dispensing according to standing order, and decrease of prescription drug abuse due to decrease in pill mills. Yet, setbacks have included the increased use of alternatives to prescription opioids such as heroin and illicitly manufactured fentanyl derivatives. As further evidence, on May 3, 2017, following the Centers for Disease Control and Prevention (CDC) declaring a national opioid epidemic, Governor Rick Scott signed Executive Order declaring a public health emergency across the state of Florida. The Florida Medicaid Drug Therapy Management Program for Behavioral Health convened a meeting on Saturday, April 29, 2017 in Tampa, FL to highlight current issues with substance use disorder (SUD) and more specifically opioid use disorder (OUD) and the role of pharmacists in management of these issues in severe mental illness (SMI). Furthermore, potential collaboration areas for policy implementation and research were discussed. The first presentation by Anna Kostric, PharmD, BCPS, entitled Opioid Use and Abuse: A Balancing Act addressed key issues such as identifying populations at high-risk for opioid misuse, abuse, and overdose; opioids used in the treatment of chronic pain with focus on Centers for Disease Control and Prevention (CDC) Guideline for Prescribing Opioids for Chronic Pain; and naloxone. The second presentation by Jill Hanson, PharmD, MBA, BCPP, entitled Opioid Summit Recap, outlined a summit convened by Sunshine Health in Tampa on January 19, 2017 to address issues and concerns around the current opioid epidemic in the United States and how the epidemic is particularly impacting Florida. Stated goals of the summit and key issues addressed included improving prescribing practices (decreasing high dosages of opioids), using the Electronic-Florida Online Reporting of Controlled Substances Evaluation (E-FORCSE), and distributing an electronic toolkit with summary guidelines, assessment tools, and miscellaneous prescriber resources. The third presentation by Joe Spillane, PharmD, DABAT, entitled Opioid & Benzodiazepine Toxicity in the Emergency Department addressed the historical perspective and current status of opioid use and abuse and benzodiazepine use and abuse in Florida, and the management and treatment of substance use in the emergency department setting. Dr. Spillane also discussed the advantages and disadvantages of naloxone at home and newer policies for obtaining naloxone without a prescription. The fourth presentation by Antionette Moore, PharmD, entitled Retail Pharmacy: The Pharmacist s Role in Substance Use Disorder and Serious Mental Illness Therapy Management focused on characteristics that make retail pharmacy the ideal setting for therapy management, barriers to drug therapy management in patients with SUD and/or SMI, and tools that may be utilized to optimize drug therapy management. (Continued on next page) page 3
4 THE PHARMACIST S CORNER Substance Use Disorder: The Pharmacist s Perspective Summary continued Following the presentations, attendees were asked to vote on the top two quality improvement ideas that they would most like to collaborate on with the Florida Medicaid Drug Therapy Management Program for Behavioral Health. The top two areas receiving a significant number of votes (greater than half of those voting) were: 1. Promoting the use of E-FORCSE: a. Providing educational seminars on registering with the prescription drug management program (PDMP), advantages and disadvantages of the current system, E-FORCSE. b. Providing feedback to clinicians regarding the impact of utilizing the PDMP on healthcare metrics. c. Determining the number of clinicians and pharmacists accessing E-FORCSE. Potentially providing incentives for clinicians showing how their utilization of the program has positively impacted care. d. Working with state agencies to have E-FORCSE integrated into the EMHR. Several participants indicated that they would be much more likely to use the PDMP if it were integrated into the EMHR that they currently use. 2. Developing ways to collaborate with prescribers: a. Implementing systems where pharmacists are contacting clinicians regarding management of patients with OUD. b. Documenting the number of contacts/interventions, and c. Documenting the outcome of these communications. d. Subsequent or follow-up opioid summits with increased involvement of various healthcare professionals to develop policies on managing patients with OUD. References: 1. Centers for Disease Control and Prevention (CDC). Drug Overdose Death Data [Internet] Dec [cited 12 May 2017]. Available from: 2. National Institute on Drug Abuse (NIDA). Miami-Dade and Broward Counties, South Florida [Internet] Feb [cited 12 May 2017]. Available from: community-epidemiology-work-group-cewg/meeting-reports/highlights-summaries-january-2014/miami. 3. State of Florida Office of the Governor. Executive Order Number [Internet]. 3 May 2017 [cited 12 May 2017]. Available from: page 4
5 MAY IS NATIONAL MENTAL HEALTH AWARENESS MONTH The Florida Medicaid Drug Therapy Management Program would like to celebrate National Mental Health Awareness month by honoring two important contributors to our Program: Dr. Daniel Castellanos and Dr. Tanya Murphy. Daniel Castellanos, MD is a child and adolescent psychiatrist who has spent his career in academic medicine dedicated to the teaching and training of students, residents, and fellows in Psychiatry. He has given numerous presentations and published on topics related to suicide and Hispanic youth, the use of novel psychoactive drugs, and education and policy development focusing on the appropriate use of psychotropic medications in children and adolescents. Dr. Castellanos is the Founding Chair of the Department of Psychiatry & Behavioral Health and Professor of Psychiatry and Behavioral Health and Pediatrics at the Florida International University Herbert Wertheim College of Medicine. Over the past nine years he has led the expansion of his Department s clinical, educational, and research programs. Today, the Department of Psychiatry & Behavioral Health is the second largest clinical department in the College of Medicine. Education and training have been an integral part of Dr. Castellanos vision and the department s mission. He has prioritized the goal of increasing medical student selection of psychiatry as a specialty. Over the past four years the department s efforts have resulted in the College of Medicine s medical students matching into psychiatry residency programs at nearly double the national rate. In partnership with Citrus Health Network, Dr. Castellanos and his faculty helped develop and obtain accreditation for a new psychiatry residency program. The novel training program is the first ACGME accredited psychiatry residency program in the country based out of a Federally Qualified Health Center and a Community Mental Health Center. Since 2015, he has also served as the College of Medicine s Assistant Dean for Graduate Medicate Education (GME) working to develop and expand GME programs in different specialties throughout the region. Dr. Castellanos is committed to developing programs that offer excellence in education, training, research, and clinical services. Dr. Castellanos was asked what he enjoyed the most about being a child and adolescent psychiatrist: Working with children & adolescents is a challenging and rewarding experience. As I have obtained more experience and wisdom, I am still aware of how much more I have to learn ( know what you don t know ). I embrace the idea of lifelong learning. I am also fortunate to be able to work with different levels of learners. I find it rewarding when I am able to help a youngster and his or her family. Children and adolescents are in the early phases of their proverbial life journey. It is personally and professionally fulfilling to be able to facilitate healthy development and help with behavioral health problems. He was also asked what he felt is most important in training future psychiatrists: Future psychiatrists face the challenge of learning the multiplicity of factors involved in understanding normal development and clinical issues. Trainees should heed caution in categorically adopting biological or psychosocial perspectives. Emerging technologies, pharmacological and biological developments should continue to be balanced with understanding the social determinants of health. Future psychiatrists are best served with figuring out how to keep up with new scientific developments, critically appraise research and how to incorporate evidence based changes into their clinical practices. (Continued on next page) page 5
6 MAY IS NATIONAL MENTAL HEALTH AWARENESS MONTH continued... The Florida Medicaid Drug Therapy Management Program would like to celebrate National Mental Health Awareness month by honoring two important contributors to our Program: Dr. Daniel Castellanos and Dr. Tanya Murphy. Dr. Tanya Murphy is the Director of the Rothman Center for Pediatric Neuropsychiatry, and holds the Maurice A. and Thelma P. Rothman Endowed Chair in Developmental Pediatrics with a joint appointment in the Department of Psychiatry at the University of South Florida in the Morsani College of Medicine. After graduating from the College of Medicine at the University of Florida (UF), Dr. Murphy stayed at UF to complete her residency in general psychiatry and fellowship in child and adolescent psychiatry. As a member of the Department of Psychiatry faculty, she served as Director of the UF Child & Adolescent Psychiatry Outpatient Program, Director of the UF Child Anxiety & Tic Disorder Clinic, and Medical Director for the UF Autism Unit. From she was Chief of the Division of Child and Adolescent Psychiatry at UF. Dr. Murphy is board-certified in psychiatry and child psychiatry. She also holds a Master of Science in Clinical Investigation. She actively participates in numerous professional organizations including the American Academy of Child and Adolescent Psychiatry (AACAP), the National Tourette Syndrome Association where she served for 13 years on the Medical Advisory Board, the International Obsessive Compulsive Foundation Scientific Advisory Board, and as a fellow in the American Psychiatric Association. With regard to research, Dr. Murphy has received several major grants from the National Institute of Mental Health and has published more than 100 peer-reviewed papers. She has extensive experience in designing and coordinating studies for pediatric clinical trials, including pediatric autoimmune neuropsychiatric disorders associated with streptococcus (PANDAS), childhood obsessive-compulsive disorder (OCD), tic disorders, anxiety disorders, and autism spectrum disorders. Her current research focuses on understanding the role of infections and the immune system in the onset of childhood psychiatric disorders and pharmacological and psychological treatments for Tourette's Syndrome and obsessive-compulsive disorder. page 6
7
The Prescription Opioid and Heroin Crisis
The Prescription Opioid and Heroin Crisis Dr. Rachel L. Levine Acting Secretary of Health and Physician General Professor of Pediatrics and Psychiatry Penn State College of Medicine Overdose deaths from
More informationPrepublication Requirements
Issued Prepublication Requirements The Joint Commission has approved the following revisions for prepublication. While revised requirements are published in the semiannual updates to the print manuals
More informationOpioid Review and MAT Clinic CDC Guidelines
1 Opioid Review and MAT Clinic CDC Guidelines January 10, 2018 Housekeeping Use chat feature to inform everyone who s at your clinic Click chat on Zoom option bar Chat Everyone the names of those who are
More informationADDRESSING THE OPIOID EPIDEMIC. Joint principles of the following organizations representing front-line physicians
ADDRESSING THE OPIOID EPIDEMIC Joint principles of the following organizations representing front-line physicians American Academy of Family Physicians American Academy of Pediatrics American College of
More informationSC MAT ACCESS. Medication Assisted Treatment Academic Community Capacity Expansion for Sustainable Success Kathleen Brady, MD, PhD, VPR, MUSC
SC MAT ACCESS Medication Assisted Treatment Academic Community Capacity Expansion for Sustainable Success Kathleen Brady, MD, PhD, VPR, MUSC Overdose Death Rates from Opiates Most important sign of a
More informationFrom Medicaid Transformation Approved Project Toolkit, June 2017
From Medicaid Transformation Approved Project Toolkit, June 2017 Domain 3: Prevention and Health Promotion Transformation projects within this domain focus on prevention and health promotion to eliminate
More informationBuilding a Comprehensive, Community-driven Prevention Approach to the Opioid Crisis in Maine
Building a Comprehensive, Community-driven Prevention Approach to the Opioid Crisis in Maine Scott M. Gagnon, MPP, PS-C Director, AdCare Educational Institute of Maine, Inc. Co-Chair, Prevention & Harm
More informationTALK (8255) Spanish Language: For hearing impaired: TTY (4889) NATIONAL CRISIS TEXT LINE
Suicide: A Rising Public Health Concern in Florida NATIONAL SUICIDE PREVENTION RESOURCES NATIONAL SUICIDE PREVENTION LIFELINE Available 24 hours per day, 7 days per week 1-800-273-TALK (8255) Spanish Language:
More informationTom Williams, MD Chief Medical Officer Director of the Division of Public Health Nebraska Department of Health and Human Services
Tom Williams, MD Chief Medical Officer Director of the Division of Public Health Nebraska Department of Health and Human Services Helping People Live Better Lives Background DHHS dynamic agency Helping
More informationTREATING OPIOID ADDICTION IN HOMELESS POPULATIONS
TREATING OPIOID ADDICTION IN HOMELESS POPULATIONS Challenges and Opportunities Providing Medication Assisted Treatment (Buprenorphine) August 18, 2016 SPEAKERS TODAY Nilesh Kalyanaraman, MD, Chief Health
More informationNew Jersey Mental Health and Addiction Providers Meeting April 26, Shereef Elnahal, M.D., M.B.A. Commissioner New Jersey Department of Health
New Jersey Mental Health and Addiction Providers Meeting April 26, 2018 Shereef Elnahal, M.D., M.B.A. Commissioner New Jersey Department of Health DOH Healthcare & Public Health Priorities Reduce disparities
More informationHHS Priorities and Actions to Support Treatment for Those with Opioid Use Disorder
HHS Priorities and Actions to Support Treatment for Those with Opioid Use Disorder Brett Giroir, U.S. Department of Health and Human Services Join the conversation at #OUDTreatment #EndTheStigma Expanding
More informationOregon s PDMP: An epidemiological assist tool
Oregon s PDMP: An epidemiological assist tool Todd Beran Center for Prevention and Health Promotion Oregon Health Authority PDMP TTAC Webinar February 13, 2013 1 Acknowledgements Lisa Millet, MSH, Section
More informationPrescription Opioid Overdose in Oregon: A public health perspective
Prescription Opioid Overdose in Oregon: A public health perspective Katrina Hedberg, MD, MPH Health Officer & State Epidemiologist Oregon Public Health Division Oregon Health Authority All-Cause Mortality,
More informationAcademic Medical School: Implementing Curriculum in Chronic Pain and Opioid Misuse. Jill M Williams, MD
Academic Medical School: Implementing Curriculum in Chronic Pain and Opioid Misuse Pain, Pain Management and the Opioid Epidemic Symposium Jill M Williams, MD Professor Psychiatry Director, Division Addiction
More informationOrange County Heroin Task Force Implementation Update. George Ralls M.D. Director of Health & Public Safety Orange County Government
Orange County Heroin Task Force Implementation Update George Ralls M.D. Director of Health & Public Safety Orange County Government Presentation Outline Overview of Data Orange County Heroin Task Force
More informationGUIDELINES FOR POST PEDIATRICS PORTAL PROGRAM
GUIDELINES FOR POST PEDIATRICS PORTAL PROGRAM Psychiatry is a medical specialty that is focused on the prevention, diagnosis, and treatment of mental, addictive, and emotional disorders throughout the
More informationOpioid Overdose in Oregon Report to the Legislature
SEPTEMBER 2018 Opioid Overdose in Oregon Report to the Legislature This report summarizes the burden of opioid overdose among Oregonians as required by ORS 432.141. It describes Oregon s progress in reducing
More informationEXECUTIVE ORDER TAKING FURTHER ACTIONS TO ADDRESS THE OPIOID OVERDOSE CRISIS
EXECUTIVE ORDER TAKING FURTHER ACTIONS TO ADDRESS THE OPIOID OVERDOSE CRISIS Gina M. Raimondo, Governor Nicole Alexander-Scott, MD, MPH, Director of Health Action Plan Strategies to Date Since 2015, we
More informationPerformance of North Carolina's System for Monitoring Prescription Drug Abuse. Session Law , Section 12F.16.(q)
Performance of North Carolina's System for Monitoring Prescription Drug Abuse Session Law 2015-241, Section 12F.16.(q) Report to the Joint Legislative Oversight Committee on Health and Human Services and
More informationLinking Opioid Treatment in Primary Care. Roxanne Lewin M.D.
Roxanne Lewin M.D. The Facts Fewer than 10 percent of individuals with an alcohol use disorder and only about 20 percent of individuals with an opioid use disorder receive specialty treatment. Many individuals
More informationAddressing the Opioid Crisis Workgroup: Treatment and Overdose Prevention
The Accountable Community for Health of King County Addressing the Opioid Crisis Workgroup: Treatment and Overdose Prevention May 7, 2018 1 Opiate Treatment & Overdose Prevention Project Goal Immediate:
More informationReducing Opioid Deaths: Arizona s Emergency Declaration & Response
Reducing Opioid Deaths: Arizona s Emergency Declaration & Response September 15, 2017 Sheila Sjolander, Assistant Director Arizona Department of Health Services Emergency Declaration On June 5, 2017, Arizona
More informationDEPARTMENT OF PSYCHIATRY. Newsletter
DEPARTMENT OF PSYCHIATRY Office of the Chair - Week of April 15-19, 2013 Website: http://www.hsc.usf.edu/psych/ Newsletter Meetings Thursday 04/18/13 8:00 a.m. Call Center Meeting Resident Lectures: 8:00
More informationOpioid Safety Initiative. Thomas Emmendorfer, PharmD Deputy Chief Consultant Pharmacy Benefits Management (PBM) Services
Opioid Safety Initiative Thomas Emmendorfer, PharmD Deputy Chief Consultant Pharmacy Benefits Management (PBM) Services 1 2 Opioid Safety Initiative (OSI) Overdose Education and Naloxone Distribution (OEND):
More informationDEPARTMENT OF PSYCHIATRY. Newsletter
DEPARTMENT OF PSYCHIATRY Office of the Chair - Week of March 4-8, 2013 Website: http://www.hsc.usf.edu/psych/ Newsletter Upcoming Grand Rounds Presentation The Morsani Center, Rooms 1013 A and B: Thursday,
More informationAetna s Initiative on the Opioid Epidemic
Aetna s Initiative on the Opioid Epidemic Christopher James D.O., M.P.H. Medical Director, BH- Mid-Atlantic Territory (JamesC1@aetna.com) July 23, 2017 HHS Data on Epidemic Every Day in the U.S. More than
More informationDEPARTMENT OF PSYCHIATRY. Newsletter
DEPARTMENT OF PSYCHIATRY Office of the Chair - Week of March 25-29, 2013 Website: http://www.hsc.usf.edu/psych/ Newsletter Upcoming Higgins Alcohol and Addictions Visiting Professor Presentation The Morsani
More informationMaternal Substance Abuse: Challenges & Opportunities for Perinatal Nurses Catherine H. Ivory, PhD, RNC-OB October, 2015
Maternal Substance Abuse: Challenges & Opportunities for Perinatal Nurses Catherine H. Ivory, PhD, RNC-OB October, 2015 Objectives Discuss the current scope of maternal substance use and abuse List examples
More informationADDING EVEN MORE SUBSTANCE TO MANAGED CARE
HEALTH WEALTH CAREER ADDING EVEN MORE SUBSTANCE TO MANAGED CARE OPTIMIZING MEDICAID TO RESPOND TO SUBSTANCE USE DISORDERS NATIONAL ACADEMY FOR STATE HEALTH POLICY 30TH ANNUAL STATE HEALTH POLICY CONFERENCE
More informationOpioid Overview Admiral Brett P. Giroir, M.D.
A S S I S TA N T S E C R E TA RY F O R H E A LT H Opioid Overview Admiral Brett P. Giroir, M.D. Assistant Secretary for Health Senior Advisor for Opioid Policy @HHS_ASH August 20, 2018 SUBSTANCE ABUSE
More informationPrescription Drug Monitoring Program Update. Rebecca R. Poston, BPharm., MHL Program Manager August 26, 2017
Prescription Drug Monitoring Program Update Rebecca R. Poston, BPharm., MHL Program Manager August 26, 2017 Objectives Brief historical overview of opioids Review of PDMP information Discuss ideas from
More informationGovernor Raimondo s Task Force on Overdose Prevention and Intervention May 9, 2018
Governor Raimondo s Task Force on Overdose Prevention and Intervention May 9, 2018 DIRECTOR NICOLE ALEXANDER-SCOTT, MD, MPH, RHODE ISLAND DEPARTMENT OF HEALTH DIRECTOR REBECCA BOSS, MA, RHODE ISLAND DEPARTMENT
More informationMedication for the Treatment of Addiction (MAT)
Medication for the Treatment of Addiction (MAT) Karol Kaltenbach, PhD Emeritus Professor of Pediatrics Sidney Kimmel Medical College at Thomas Jefferson University Terminology: Words Matter Medication
More informationMayors Opioid Summit PATTERNS AND TRENDS OF THE OPIOID EPIDEMIC IN BROWARD COUNTY TYPES OF OPIOIDS DEFINITION OF OPIOID. Pill Press from China
The Opioid Epidemic In Broward County 8/24/217 Mayors Opioid Summit PATTERNS AND TRENDS OF THE OPIOID EPIDEMIC IN BROWARD COUNTY Jim Hall Senior Epidemiologist Center for Applied Research on Substance
More informationProgress Report and 2018 Legislative Opportunities. Maine Opiate Collaborative Recommendations
Progress Report and 2018 Legislative Opportunities related to the Maine Opiate Collaborative Recommendations April 2018 A. Destigmatize substance use disorders within the law enforcement profession 1.
More informationPennsylvania s Opioid Crisis: Data and Strategies to Combat It
Data and Strategies to Combat It May 8, 2018 Phillip M. Burrell Director, Research & Data Analytics The Hospital + Healthsystem Association of Pennsylvania Agenda The PA opioid crisis Trends Responses
More informationOpiate Use Disorder and Opiate Overdose
Opiate Use Disorder and Opiate Overdose Irene Ortiz, MD Medical Director Molina Healthcare of New Mexico and South Carolina Clinical Professor University of New Mexico School of Medicine Objectives DSM-5
More informationAddressing the Opioid Epidemic in Tennessee
Addressing the Opioid Epidemic in Tennessee A Multidisciplinary Approach Melissa McPheeters, PhD, MPH Director, Informatics and Public Health Analytics 26 108 733 *Source: CDC References Centers for
More informationThe Opioid Epidemic and PerformRx s Approach to Address It: A Collaborative Model with PBM, Payor and Behavioral Health
The Opioid Epidemic and PerformRx s Approach to Address It: A Collaborative Model with PBM, Payor and Behavioral Health Andrea Gelzer, M.D., M.S., FACP Senior Vice President and Corporate Chief Medical
More informationThe Oregon Opioid Initiative. State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division
The Oregon Opioid Initiative State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division Disclosure No disclosures 2 Learning Objectives Learner will be able
More informationOutcomes of Infants with Neonatal Abstinence Syndrome
Outcomes of Infants with Neonatal Abstinence Syndrome Caroline O. Chua, MD, FAAP Medical Director, Division of Neonatology Director, Neonatal Follow Up Clinic Nemours Children s Hospital Orlando, Florida
More informationOregon Opioid Overdose Prevention Initiative
Oregon Opioid Overdose Prevention Initiative Katrina Hedberg, MD, MPH Health Officer & State Epidemiologist Oregon Public Health Division Oregon Association of Hospitals & Health Systems February 2017
More informationUniversity of South Florida OCD, Anxiety, and Related Disorders Behavioral Treatment Program
OCD and Related Disorders Clinic Profile University of South Florida OCD, Anxiety, and Related Disorders Behavioral Treatment Program Clinic/Program Director: Adam B. Lewin, PhD, ABPP Name of Intake Coordinator:
More informationManaged Care Pushes for Safer Opioid Oversight
Page 1 of 6 Clinical AUGUST 11, 2017 Managed Care Pushes for Safer Opioid Oversight High-risk pain Rx eyed Denver Health systems haven t escaped the nation s ongoing opioid crisis, as evidenced by surging
More informationBattling Opioid Addiction: Public Policy and Healthcare Strategies for an Epidemic
Battling Opioid Addiction: Public Policy and Healthcare Strategies for an Epidemic Speakers: Margarita Pereyda, M.D., Principal, Moderator: Carl Mercurio, Information Services September 29, 2015 HealthManagement.com
More informationOpioid Use and Other Trends
Opioid Use and Other Trends National Overview Across the nation communities are struggling with a devastating increase in the number of people misusing opioid drugs, leading many to identify the current
More informationMANAGING THE COSTS OF THE OPIOID EPIDEMIC IN WISCONSIN. State Senator Alberta Darling
MANAGING THE COSTS OF THE OPIOID EPIDEMIC IN WISCONSIN State Senator Alberta Darling A NATIONAL PROBLEM According to the 2014 National Survey on Drug Use and Health: 435,000 Americans have used heroin
More informationThe Opioid Crisis among the Privately Insured
The Opioid Crisis among the Privately Insured The Opioid Abuse Epidemic as Documented in Private Claims Data A FAIR Health White Paper, July 2016 Copyright 2016, FAIR Health, Inc. Summary The United States
More informationScience = Solutions For Substance Use Disorders and Infant Outcomes. Wilson M. Compton, M.D., M.P.E. Deputy Director National Institute on Drug Abuse
Science = Solutions For Substance Use Disorders and Infant Outcomes Wilson M. Compton, M.D., M.P.E. Deputy Director National Institute on Drug Abuse Science = Solutions Increased Opioid Mortality: Greater
More informationBuprenorphine Access in California
Buprenorphine Access in California James J. Gasper, PharmD, BCPP Pharmacy Benefits Division Department of Health Care Services james.gasper@dhcs.ca.gov Source: CDPH Vital Statisitics Death Statistical
More informationPragmatic and Creative Responses to the Opioid Crisis in Connecticut
Focusing on Highly Vulnerable Populations Track Pragmatic and Creative Responses to the Opioid Crisis in Connecticut A special thanks to our presenting sponsor: Presenters: Shawn Lang Deputy Director AIDS
More informationMaternal and Child Health, Substance Abuse Ohio Department of Health, Bureau of Maternal Child and Family Health
Maternal and Child Health, Substance Abuse Ohio Department of Health, Bureau of Maternal Child and Family Health Columbus, Ohio Assignment Description The rapid advance of the opiate crisis has had far
More informationMental and Behavioral Health
Mental and Behavioral Health Mental Health Poor mental health is a major source of distress, disability, and social burden. In any given year, as many as one in five adults in the United States have a
More informationOHIO S OPIOID DRUG OVERDOSE EPIDEMIC: CONTRIBUTING FACTORS AND ONGOING PREVENTION EFFORTS
OHIO S OPIOID DRUG OVERDOSE EPIDEMIC: CONTRIBUTING FACTORS AND ONGOING PREVENTION EFFORTS DEFINITIONS Opiate- originate from naturally-occurring elements found in the opium poppy plant. These drugs are
More informationThe Magnitude of the Problem
Testimony on Senate Bill 860 Criminal Justice and Addiction Treatment Act Drs. Sheryl Ryan, Chief Adolescent Medicine and Leslie Walker-Harding, Chair of the Department of Pediatrics Penn State Health
More informationNational Academy of Medicine Action Collaborative: Countering the US Opioid Epidemic
National Academy of Medicine Action Collaborative: Countering the US Opioid Epidemic Admiral Brett P. Giroir, M.D. Assistant Secretary for Health Senior Advisor for Opioids and Mental Health Policy @HHS_ASH
More informationSubstance Use Disorders: A Path Forward for Michigan
Substance Use Disorders: A Path Forward for Michigan DEBRA A. PINALS, M.D. MEDICAL DIRECTOR BEHAVIORAL HEALTH AND FORENSIC PROGRAMS MICHIGAN DEPARTMENT OF HEALTH AND HUMAN SERVICES Tackling the opiate
More informationTHA Medication Safety Summit. Wesley Geminn, PharmD, BCPP
THA Medication Safety Summit Wesley Geminn, PharmD, BCPP Current Trends: Overdose Deaths in 2017 72,000 Or 197 per day 8 per hour National Opioid Overdose Statistics https://www.drugabuse.gov/related-topics/trendsstatistics/overdose-death-rates
More informationSubmitted to the House Energy and Commerce Committee. Federal Efforts to Combat the Opioid Crisis
STATEMENT FOR THE RECORD Submitted to the House Energy and Commerce Committee Federal Efforts to Combat the Opioid Crisis October 25, 2017 America s Health Insurance Plans 601 Pennsylvania Avenue, NW Suite
More informationMAT IN PREGNANCY KAYLA LIFE STAGE 1: ADOLESCENCE LIFE STAGE 2: EARLY ADULTHOOD. family History of addiction. addiction to oral opioids
MAT IN PREGNANCY R. COREY WALLER MD, MS PRINCIPAL, HEALTH MANAGEMENT ASSOCIATES FACULTY, INSTITUTE FOR HEALTHCARE INNOVATION (IHI) CHAIR, LEGISLATIVE ADVOCACY COMMITTEE, ASAM KAYLA LIFE STAGE 1: ADOLESCENCE
More information4/19/2018. Opioid Use Disorder in Pregnancy OBJECTIVES ANTENATAL TESTING
Opioid Use Disorder in Pregnancy 2017 Recommendations from ACOG and The Pew Charitable Trust KATHY D. HARTKE, MD, LEGISLATIVE CO-CHAIR AND IMMEDIATE PAST CHAIR, WISCONSIN SECTION OF THE AMERICAN COLLEGE
More informationOpioid Prescribing Improvement Program
Opioid Prescribing Improvement Program Jeff Schiff, MD, MBA, Medical Director of Minnesota Health Care Programs Sarah Rinn, MPH, Opioid Prescribing Improvement Program Coordinator Agenda Opioid Prescribing
More informationOpioid Data for Local Governments in North Carolina
Opioid Data for Local Governments in North Carolina Mary Beth Cox, Stacy Taylor, and Adam Lovelady October 10, 2018 Speakers Adam Lovelady Associate Professor UNC School of Government Mary Beth Cox Substance
More informationSubstance Abuse. Among current drinkers, men in nonmetro areas consume 5 or more drinks in one day than those in metro areas (56% vs.
Framing the Issue Substance Abuse Among current drinkers, men in nonmetro areas consume 5 or more drinks in one day than those in metro areas (56% vs. 48-52%) Periodic heavy drinking more common among
More informationAddiction to Opioids. Marvin D. Seppala, MD Chief Medical Officer
Addiction to Opioids Marvin D. Seppala, MD Chief Medical Officer Mayo Clinic Opioid Conference: Evidence, Clinical Considerations and Best Practice Friday, September 30, 2016 26 y.o. female from South
More informationImplementing the 2017 President s Challenge: Primary, Secondary & Tertiary Prevention of Addiction & Substance Misuse
Implementing the 2017 President s Challenge: Primary, Secondary & Tertiary Prevention of Addiction & Substance Misuse Jay Butler, MD, President of ASTHO, Chief Medical Officer, Alaska Department of Health
More informationTITLE NALOXONE STATEWIDE STANDING ORDER UPDATE & NARCAN ACCESS ONE-DAY EVENT
TITLE NALOXONE STATEWIDE STANDING ORDER UPDATE & NARCAN ACCESS ONE-DAY EVENT WELCOME Kate Gainer, PharmD Executive Vice President and CEO Iowa Pharmacy Association PRESENTER Kevin Gabbert, LISW, IAADC
More informationPRESCRIBING GUIDELINES
Ohio Department of Health RESPONSE TO OHIO S PRESCRIPTION DRUG OVERDOSE EPIDEMIC: PRESCRIBING GUIDELINES MIPA CONFERENCE PREVENTING INJURY: FROM RESEARCH TO PRACTICE TO PEOPLE SEPTEMBER 30, 2013 Christy
More informationBuprenorphine Prescribing as a Patient- Centered Medical Home Enhancement
Buprenorphine Prescribing as a Patient- Centered Medical Home Enhancement TANNER NISSLY DO, BOB LEVY MD FASAM, MICHELE MANDRICH MSW, CMPE AS YOU ENTER, PLEASE SET UP TO PARTICIPATE IN OUR POLL EVERYWHERE
More informationProgress Report Maine Opiate Collaborative Recommendations. on the. October 2018
Progress Report on the 2016 Maine Opiate Collaborative Recommendations October 2018 MAINE OPIATE COLLABORATIVE PROGRESS REPORT Prevention & Harm Reduction October 2018 RECOMMENDATIONS STRATEGIES 2018 LEGISLATIVE
More informationStrategies for Federal Agencies
Confronting Pain Management and the Opioid Epidemic Strategies for Federal Agencies Over the past 25 years, the United States has experienced a dramatic increase in deaths from opioid overdose, opioid
More informationMedication-Assisted Treatment (MAT) Overview
Medication-Assisted Treatment (MAT) Overview 2014 Opiate Conference: Don t Get Me Started Hyatt Regency, Columbus, Ohio June 30-July 1, 2014 Christina M. Delos Reyes, MD Medical Consultant, Center for
More informationSAFE PRESCRIBING: RULES AND REGULATIONS. Michelle Y. Owens, MD MS State Board of Medical Licensure June 30, 2017
SAFE PRESCRIBING: RULES AND REGULATIONS Michelle Y. Owens, MD MS State Board of Medical Licensure June 30, 2017 DISCLOSURES I have no financial disclosures. OBJECTIVES Discuss the significance of the opiate
More informationAddressing Challenges Together, One Rock at a Time
Addressing Challenges Together, One Rock at a Time PAMELA SCHWEITZER, PHARM.D., BCACP ASSISTANT SURGEON GENERAL REAR ADMIRAL (RADM), U.S. PUBLIC HEALTH SERVICE E-MAIL: PAMELA.SCHWEITZER@CMS.HHS.GOV @USPHSPHARMACY
More informationCDC Guideline for Prescribing Opioids for Chronic Pain. Centers for Disease Control and Prevention National Center for Injury Prevention and Control
CDC Guideline for Prescribing Opioids for Chronic Pain Centers for Disease Control and Prevention National Center for Injury Prevention and Control THE EPIDEMIC Chronic Pain and Prescription Opioids 11%
More informationThe Future of Prevention: Addressing the Prescription Drug Abuse and the Opioid/Heroin Epidemic in our Country
Integrating Primary and Behavioral Health Care Through the Lens of Prevention July 14, 2016 New Orleans, Louisiana The Future of Prevention: Addressing the Prescription Drug Abuse and the Opioid/Heroin
More informationVIRGINIA S OPIOID & HEROIN OVERDOSE EPIDEMIC
1 VIRGINIA S OPIOID & HEROIN OVERDOSE EPIDEMIC Virginia Association of Counties November 14, 2016 The Honorable William A. Hazel, Jr., M.D. Secretary of Health and Human Resources 1999 - Estimated drug
More informationMedicaid and the Opioid Crisis
Medicaid and the Opioid Crisis Erica Floyd Thomas Bureau Chief of Medicaid Policy Agency for Health Care Administration Presented to: Medical Care Advisory Committee March 20, 2018 1 Florida Medicaid Covers
More informationImplementing Pain and Opioid Management Guidelines in Primary Care Practice
Implementing Pain and Opioid Management Guidelines in Primary Care Practice Objectives 1. What is the issue? 2. Why use a dedicated dissemination & implementation process? a. Historical perspective Cooperative
More informationAdvancing the Care of Pregnant and Parenting Women with Opioid Use Disorder and their Infants: A Foundation for Clinical Guidance
Advancing the Care of Pregnant and Parenting Women with Opioid Use Disorder and their Infants: A Foundation for Clinical Guidance Karol Kaltenbach, PhD Emeritus Professor of Pediatrics Sidney Kimmel Medical
More informationPresentation Objectives
Oregon s PDMP 101 Lisa Millet, MSH, Section Manager Injury and Violence Prevention Section Center for Prevention and Health Promotion Oregon Health Authority Eugene Oregon PDO Summit April 20, 2016 1 Presentation
More informationPROJECT DOVE. Improving Maternal and Neonatal Health Through Safer Opioid Prescribing
PROJECT DOVE Improving Maternal and Neonatal Health Through Safer Opioid Prescribing PARTNERS SUPPORT Bureau of Justice Assistance, Department of Justice Rhode Island Opportunity Non-medical prescription
More informationAn Introduction to the Opioid Epidemic: Working Together To End The Nation s Opioid Epidemic
Morehouse School of Medicine Department of Psychiatry & Behavioral Sciences HBCU-Center for Excellence in Behavioral Health Behavioral Health Webinar Series An Introduction to the Opioid Epidemic: Working
More informationWith your help, our goal is to protect millions more against serious illness through the development of new vaccines and other preventions.
Millions of children are alive, healthy, and have grown to productive adulthood because of what our scientists have taught the world through research. The Hib vaccine alone has saved more than 660,000
More informationGoToWebinar Housekeeping: Attendee participation
GoToWebinar Housekeeping: Attendee participation Your Participation Join audio: Choose Mic & Speakers to use your computer for audio. Not recommended for desktop units but works with laptops If not using
More informationMay 25, Drug Overdose Update & Response: Combatting Opioid Overdose
May 25, 2017 Drug Overdose Update & Response: Combatting Opioid Overdose Overview The Problem -Overdose in North Carolina (and a little nationally) -Other associated health threats PDAAC-NC s Response
More informationOpioid Use and Misuse: History, Trends, And The Oregon Opioid Initiative
Opioid Use and Misuse: History, Trends, And The Oregon Opioid Initiative John W. McIlveen, Ph.D., LMHC, State Opioid Treatment Authority, Oregon Health Authority, Addictions and Mental Health Division
More informationNOWS The Time Caring for the Infant with Neonatal Opiate Withdrawal Syndrome
NOWS The Time Caring for the Infant with Neonatal Opiate Withdrawal Syndrome Meghan Howell, MD FAAP Assistant Professor of Pediatrics Clinical Director, Tulane NICU Graduate Clinic Tulane University School
More informationSuccessful Prevention Strategies to Address the Opioid Crises
Successful Prevention Strategies to Address the Opioid Crises Shannon Breitzman, MSW, Principal Denver Office Lindsey Kato, MPH, CHES, Consultant Denver Office 1 LEARNING OBJECTIVES + Find out how to effectively
More informationEnd the Epidemic. Miami-Dade County COMPREHENSIVE COMMUNITY PREVENTION ACTION PLAN
End the Epidemic Miami-Dade County COMPREHENSIVE COMMUNITY PREVENTION ACTION PLAN 2018 2021 Miami-Dade County along with the State of Florida and the Nation are dramatically impacted by an Opioid Epidemic
More informationThe Opioid Crisis in Kentucky. Doug Oyler, PharmD Director, Office of Opioid Safety UK HealthCare
The Opioid Crisis in Kentucky Doug Oyler, PharmD Director, Office of Opioid Safety UK HealthCare Discuss the role of opioid prescribing in creating and sustaining the crisis Describe components and initiatives
More informationNeonatal Abstinence Syndrome (NAS)
Neonatal Abstinence Syndrome (NAS) Jodi Jackson, MD Neonatologist Children's Mercy Hospital Associate Professor of Pediatrics University of Missouri-Kansas City School of Medicine Medical director NICU
More informationTalking with your doctor
SUBOXONE (buprenorphine and naloxone) Sublingual Film (CIII) Talking with your doctor Opioid dependence can be treated. Talking with your healthcare team keeps them aware of your situation so they may
More informationSeptember 1, The Honorable Tom Price, MD Secretary Department of Health and Human Services 200 Independence Avenue SW Washington, DC 20201
September 1, 2017 The Honorable Tom Price, MD Secretary Department of Health and Human Services 200 Independence Avenue SW Washington, DC 20201 Dear Secretary Price: The National Association of County
More informationOpioid epidemic and PEHP
Opioid epidemic and PEHP Agenda Overview of opioid crisis Utah perspective PEHP: clinical interventions Impact of interventions Why are we here? In the 1990s, the medical establishment came to believe
More informationRevised 9/30/2016. Primary Care Provider Pain Management Toolkit
Revised 9/30/2016 Primary Care Provider Pain Management Toolkit TABLE OF CONTENTS 1. INTRODUCTION Page 1 2. NON-OPIOID SERVICES &TREATMENTS FOR CHRONIC PAIN Page 2 2.1 Medical Services Page 2 2.2 Behavioral
More informationCONTINUING EDUCATION FOR PRESCRIBERS OF CONTROLLED SUBSTANCES. Statutory Provision S.L SECTION 11F.11.(a)
CONTINUING EDUCATION FOR PRESCRIBERS OF CONTROLLED SUBSTANCES Statutory Provision S.L. 2017-57 SECTION 11F.11.(a) Report to the Joint Legislative Oversight Committee on Health and Human Services By North
More informationJust Out of Reach: Women Who Use Drugs, Stigma and Barriers to Care Erin Bortel and Lyla Hunt AIDS Institute Office of Drug User Health
Just Out of Reach: Women Who Use Drugs, Stigma and Barriers to Care Erin Bortel and Lyla Hunt AIDS Institute Office of Drug User Health March 12, 2018 Envisioning a socially just system where all New Yorkers
More informationASTHO President s Challenge 15 x 15: Reduce Prescription Drug
ASTHO President s Challenge 15 x 15: Reduce Prescription Drug Misuse and Deaths 15% by 2015 Terry Cline, Ph.D. Commissioner of Health Oklahoma Secretary of Health and Human Services Prescription drugs
More information